Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Hosted on MSN7d
FDA approves Spravato, nasal spray derived from KetamineThe FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback